Yuanting T. Gu
1 Jianshe East Road
Zhengzhou, 450052, China
Zhengzhou, 450052, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 74 publications
Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study.
Journal: Therapeutic advances in medical oncology
Published: March 19, 2024
Application of Multidisciplinary Diagnosis and Treatment (MDT) clinical teaching model in the clinical teaching of some undergraduates of breast diseases in surgery.
Journal: BMC medical education
Published: March 06, 2024
Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab.
Journal: Breast cancer (Dove Medical Press)
Published: February 21, 2024
Retraction Note: Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer.
Journal: Cell death & disease
Published: November 10, 2023
Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study.
Journal: World journal of surgical oncology
Published: August 14, 2023
Circ_0001387 regulates SKA2 to accelerate breast cancer progression through miR-136-5p.
Journal: Thoracic cancer
Published: January 11, 2023
Catheter malposition analysis of totally implantable venous access port in breast cancer patients.
Journal: Frontiers in surgery
Published: October 05, 2022
A rapid reduction in tumor size by cyclin-dependent kinase inhibition in hormone receptor-positive postpartum breast cancer: a case report of two patients and a review of the literature.
Journal: Annals of translational medicine
Published: September 20, 2022
Corrigendum to "Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers" [Semin. Cancer Biol. 83 (2022) 556-569].
Journal: Seminars in cancer biology
Published: July 19, 2022
Retraction Note to: Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation.
Journal: Molecular cancer
Published: July 12, 2022
Last Updated: 09/26/2026